Literature DB >> 27614798

Present Yourself! By MHC Class I and MHC Class II Molecules.

Kenneth L Rock1, Eric Reits2, Jacques Neefjes3.   

Abstract

Since the discovery of MHC molecules, it has taken 40 years to arrive at a coherent picture of how MHC class I and MHC class II molecules really work. This is a story of the proteases and MHC-like chaperones that support the MHC class I and II molecules in presenting peptides to the immune system. We now understand that the MHC system shapes both the repertoire of presented peptides and the subsequent T cell response, with important implications ranging from transplant rejection to tumor immunotherapies. Here we present an illustrated review of the ins and outs of MHC class I and MHC class II antigen presentation.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  MHC class I; MHC class II; antigen presentation; autoimmune diseases; transplantation; tumor immunology

Mesh:

Substances:

Year:  2016        PMID: 27614798      PMCID: PMC5159193          DOI: 10.1016/j.it.2016.08.010

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  129 in total

1.  Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo.

Authors:  J S Haurum; I B Høier; G Arsequell; A Neisig; G Valencia; J Zeuthen; J Neefjes; T Elliott
Journal:  J Exp Med       Date:  1999-07-05       Impact factor: 14.307

Review 2.  DRiPs solidify: progress in understanding endogenous MHC class I antigen processing.

Authors:  Jonathan W Yewdell
Journal:  Trends Immunol       Date:  2011-09-29       Impact factor: 16.687

3.  Cross-presentation by intercellular peptide transfer through gap junctions.

Authors:  Joost Neijssen; Carla Herberts; Jan Wouter Drijfhout; Eric Reits; Lennert Janssen; Jacques Neefjes
Journal:  Nature       Date:  2005-03-03       Impact factor: 49.962

Review 4.  The wide diversity and complexity of peptides bound to class II MHC molecules.

Authors:  Anish Suri; Scott B Lovitch; Emil R Unanue
Journal:  Curr Opin Immunol       Date:  2005-11-28       Impact factor: 7.486

5.  Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1.

Authors:  J H Brown; T S Jardetzky; J C Gorga; L J Stern; R G Urban; J L Strominger; D C Wiley
Journal:  Nature       Date:  1993-07-01       Impact factor: 49.962

6.  A human TAPBP (TAPASIN)-related gene, TAPBP-R.

Authors:  Michelle S Teng; Richard Stephens; Louis Du Pasquier; Tom Freeman; Jonathan A Lindquist; John Trowsdale
Journal:  Eur J Immunol       Date:  2002-04       Impact factor: 5.532

7.  T-cell engagement of dendritic cells rapidly rearranges MHC class II transport.

Authors:  Marianne Boes; Jan Cerny; Ramiro Massol; Marjolein Op den Brouw; Tom Kirchhausen; Jianzhu Chen; Hidde L Ploegh
Journal:  Nature       Date:  2002-08-29       Impact factor: 49.962

8.  Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages.

Authors:  M Kovacsovics-Bankowski; K Clark; B Benacerraf; K L Rock
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

9.  Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay.

Authors:  M J Bevan
Journal:  J Exp Med       Date:  1976-05-01       Impact factor: 14.307

10.  Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self.

Authors:  Fiyaz Mohammed; Mark Cobbold; Angela L Zarling; Mahboob Salim; Gregory A Barrett-Wilt; Jeffrey Shabanowitz; Donald F Hunt; Victor H Engelhard; Benjamin E Willcox
Journal:  Nat Immunol       Date:  2008-10-05       Impact factor: 25.606

View more
  172 in total

Review 1.  Immunotherapy and predictive immunologic profile: the tip of the iceberg.

Authors:  Tatiana Cunha Pereira; Paulo Rodrigues-Santos; Jani Sofia Almeida; Fábio Rêgo Salgueiro; Ana Raquel Monteiro; Filipa Macedo; Rita Félix Soares; Isabel Domingues; Paula Jacinto; Gabriela Sousa
Journal:  Med Oncol       Date:  2021-03-31       Impact factor: 3.064

2.  Improved peptide-MHC class II interaction prediction through integration of eluted ligand and peptide affinity data.

Authors:  Christian Garde; Sri H Ramarathinam; Emma C Jappe; Morten Nielsen; Jens V Kringelum; Thomas Trolle; Anthony W Purcell
Journal:  Immunogenetics       Date:  2019-06-10       Impact factor: 2.846

3.  Peripheral blood mononuclear cell proteome profile in Behçet's syndrome.

Authors:  Asli Kirectepe Aydin; Yeşim Özgüler; Didar Uçar; Murat Kasap; Gürler Akpınar; Emire Seyahi; Eda Tahir Turanli
Journal:  Rheumatol Int       Date:  2019-08-14       Impact factor: 2.631

Review 4.  T cell antigen discovery.

Authors:  Alok V Joglekar; Guideng Li
Journal:  Nat Methods       Date:  2020-07-06       Impact factor: 28.547

5.  HLA-DO Modulates the Diversity of the MHC-II Self-peptidome.

Authors:  Padma P Nanaware; Mollie M Jurewicz; John D Leszyk; Scott A Shaffer; Lawrence J Stern
Journal:  Mol Cell Proteomics       Date:  2018-12-20       Impact factor: 5.911

6.  A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8+ T-cell Responses, Impacting Tumor Challenge.

Authors:  Elizabeth K Duperret; Alfredo Perales-Puchalt; Regina Stoltz; Hiranjith G H; Nitin Mandloi; James Barlow; Amitabha Chaudhuri; Niranjan Y Sardesai; David B Weiner
Journal:  Cancer Immunol Res       Date:  2019-01-24       Impact factor: 11.151

7.  Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity.

Authors:  Hélène G Bazin; Laura S Bess; Mark T Livesay; Yufeng Li; Van Cybulski; Shannon M Miller; David A Johnson; Jay T Evans
Journal:  Bioorg Med Chem Lett       Date:  2020-01-22       Impact factor: 2.823

8.  HLA-DR+ NK cells are mostly characterized by less mature phenotype and high functional activity.

Authors:  Sofya A Erokhina; Maria A Streltsova; Leonid M Kanevskiy; William G Telford; Alexander M Sapozhnikov; Elena I Kovalenko
Journal:  Immunol Cell Biol       Date:  2017-12-19       Impact factor: 5.126

9.  Markov state modeling reveals alternative unbinding pathways for peptide-MHC complexes.

Authors:  Jayvee R Abella; Dinler Antunes; Kyle Jackson; Gregory Lizée; Cecilia Clementi; Lydia E Kavraki
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-12       Impact factor: 11.205

10.  Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy.

Authors:  Marco Galluzzo; Simone D'Adamio; Elena Campione; Luca Bianchi; Marina Talamonti
Journal:  Mol Diagn Ther       Date:  2018-12       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.